Rosen Law Firm Investigates UnitedHealth for Fiduciary Breaches
Minnesota, Saturday, 22 February 2025.
The Rosen Law Firm is urging UnitedHealth Group investors experiencing substantial losses to consider legal action due to potential fiduciary breaches by company leaders.
DOJ Investigation Triggers Legal Scrutiny
On February 21, 2025, UnitedHealth Group (NYSE: UNH) came under investigation by the United States Department of Justice regarding its billing practices, particularly concerning Medicare Advantage payments [1][2]. The DOJ’s civil fraud investigation focuses on patient diagnoses that may have resulted in higher payments from the Medicare Advantage program, affecting more than half of Medicare recipients [2][3]. This development has caused UnitedHealth’s stock to decline by approximately 9% [2][3].
Multiple Law Firms Launch Investigations
The legal landscape surrounding UnitedHealth has rapidly expanded, with multiple prominent law firms initiating investigations. Rosen Law Firm, a global investor rights law firm, announced its investigation into potential breaches of fiduciary duties by UnitedHealth’s directors and officers [1]. Similarly, Edelson Lechtzin LLP launched a parallel investigation into potential violations of federal securities laws [2][3]. These investigations stem from concerns about UnitedHealth’s acquisitions of healthcare providers and data companies [2].
Impact on Investors and Legal Options
As of February 22, 2025, no class action has been certified in this case [2][3]. This means investors currently have the freedom to select their own legal representation [3]. The Rosen Law Firm, which has previously achieved significant victories including the largest securities class action settlement against a Chinese company [1], is encouraging affected shareholders to visit their website for more information about their rights and potential claims [1].
Broader Industry Context
This investigation comes at a time when the Biden administration has been working to restrict payments to Medicare Advantage plans, following concerns raised by lawmakers, watchdogs, and whistleblowers about potential waste of tax dollars [3]. The current investigation could have significant implications for UnitedHealth’s operations and investor confidence in the healthcare insurance sector [GPT].